Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Using MDxHealth's Technology in Colon Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Exact Sciences will use a methylation biomarker and methylation-specific PCR technology from MDxHealth in its Cologuard non-invasive DNA colon cancer screening test, MDxHealth said today.

Exact Sciences initially licensed the marker and platform technology in July, before MDxHealth changed its name from OncoMethylome. The company has been evaluating the technology since that time.

MDxHealth said that Exact's decision to move forward with the test has triggered a milestone payment of an undisclosed amount. The company is also entitled to royalties on sales of the test once it is commercialized.

Exact Sciences said that in a study involving samples from 1,100 patients, Cologuard was shown to detect 64 percent of colorectal pre-cancers and 85 percent of colorectal cancers.

The company is now preparing to enroll several thousand patients in a prospective trial to obtain approval from the US Food and Drug Administration. It expects to complete the trial in 2012.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.